Bevacizumab (Avastin®) for non-small cell lung cancer
Hayes, Inc.
Record ID 32012000178
English
Authors' recommendations:
Bevacizumab (Avastin®; Genentech Inc.) is a recombinant human monoclonal immunoglobulin G (IgG1) antibody that targets the circulating vascular endothelial growth factor (VEGF) and inhibits its binding to VEGF receptors, thereby preventing its proangiogenic activity. It is approved for use as a first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic nonsquamous non-small cell lung cancer (NSCLC), in combination with carboplatin and paclitaxel. Bevacizumab has also been investigated as second-line therapy in patients with NSCLC who have failed other therapies.
Details
Project Status:
Completed
Year Published:
2011
URL for published report:
http://www.hayesinc.com/hayes/crd/?crd=6895
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
- Antibodies, Monoclonal, Humanized
- Bevacizumab
- Antineoplastic Agents, Immunological
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
<p>HAYES, Inc.</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.